CRL tied to third‑party compliance

The FDA told Incyte on February 27, 2026 that it would not approve the company’s supplemental biologics license application for retifanlimab (Zynyz) plus platinum chemotherapy in metastatic non–small cell lung cancer. (sec.gov) The reason was not the drug’s clinical performance. The agency’s Complete Response Letter cites inspection findings at a third‑party fill‑finish facility — Catalent Indiana — and names that facility’s regulatory compliance as the sole approvability issue. (sec.gov) (onclive.com) Retifanlimab’s Phase 3 POD1UM‑304 program produced the efficacy data that underpinned the sBLA, including overall survival benefits that Incyte previously reported. (biospace.com) The FDA’s action therefore pauses a label expansion driven by manufacturing concerns rather than safety or efficacy shortcomings. (onclive.com) Fill‑finish is the stage where sterile drug product is aseptically filled into vials or syringes, labeled, and packaged. Problems in that operation can affect sterility assurance, batch records, and lot release traceability — the very elements regulators inspect to ensure each marketed vial is reliably produced. No clinical trial data will fix a contaminated or unclearly documented batch; a clean inspection will. (onclive.com) Incyte already markets Zynyz for other indications, so the regulatory hit here is narrowly about expanding the indication to first‑line metastatic NSCLC, not about pulling an existing on‑market label. (zynyzhcp.com) That distinction matters for patient safety teams: active marketed product surveillance continues, but anticipated new‑use exposures and the safety signal landscape tied to a larger NSCLC population are delayed until the manufacturing questions are resolved. (sec.gov) For pharmacovigilance leaders, the practical takeaway is immediate and concrete. Contracts and quality agreements that give sponsors timely audit access, corrective‑action visibility, and data escrow for batch records now carry more weight than before. If a CRO or CMOs’ inspection findings can block approvals despite clean clinical data, sponsors must accelerate vendor oversight, sample retention strategies, and end‑to‑end lot traceability to enable rapid root‑cause assessment and targeted recalls if needed. (onclive.com) Regulatory strategy must also change. Coordinate regulatory, quality, and PV teams earlier during sBLA activities so inspection findings feed into risk management files, signal detection thresholds, and communication plans. Prepare rapid‑activation pharmacovigilance protocols that can be deployed if manufacturing remediation requires lot holds or market notifications. These steps preserve the integrity of safety databases and minimize noise when exposure suddenly changes. (sec.gov) Incyte says it will work with the FDA and Catalent Indiana to address the findings and support a potential resubmission. (sec.gov) The clock now runs on remediation documentation, re‑inspection scheduling, and demonstrable corrective actions — the concrete items FDA will want to see before it reconsiders approval. (onclive.com)